The U.S. Food and Drug Administration has cleared Waltham, Mass.-based EarlySense's EarlySense 2.0 bedside monitoring system, according to a news release by the company.
The new bedside monitoring system continuously measures heart rate, breath rate and motion without requiring patient contact, according to the release. Constantly monitoring vitals and receiving reports of vital trends can help reduce the potential for an adverse event, according to the release.
More Articles on the FDA:
FDA Clears Smiths Medical to Market Patient-Controlled Pain
FDA Approves Gore Medical's Viabhan Endoprosthesis Devices Use Expansion
FDA, European Medicines Agency to Collaborate on Generic Drug Approvals